Dynamic phenotypes of preclinical and clinical obesity in relation to new‐onset cancer risk: A longitudinal analysis from the UK biobank
Authors' conclusion
Obesity-induced dysfunction was significantly associated with cancer risk. For future clinical practice, the early identification and intervention of clinical obesity and obesity-induced dysfunctions are of critical importance for reducing cancer risks.
Study context
- Population
- UK Biobank participants; six clusters by baseline and follow-up obesity-induced dysfunction status
- Participants
- 220,016 participants
- Exposure
- Clusters of obesity and obesity-induced dysfunction status vs Cluster 1
- Outcome
- Cancer incidence
- Follow-up
- Mean 11.0 years
Methodological detailslandmark analysis, UK Biobank
- Landmark analysis
- UK Biobank
Main finding
As reported in the abstract
Cancer incidence (multivariable-adjusted)
Each group vs cluster 1Hazard ratio (95% CI)
Cluster 5highest risk
3.17(3.05–3.29)
Cluster 4lowest risk
0.88(0.85–0.92)
- Total cancer incidence
- 24 066
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Cancer mortality (fully adjusted)Cluster 6vs Cluster 1Highest | 1.82 (1.65–2.00) | |
| 0.512Hazard ratio (log scale) |
Site-specific cancers
- Consistently higher cancer risks in Clusters 5 and 6 across various cancer types, notably pancreatic cancer incidence and prostate or bladder cancer mortality
Original publication
Dynamic phenotypes of preclinical and clinical obesity in relation to new‐onset cancer risk: A longitudinal analysis from the UK biobank. Diabetes Obes Metab. Published 2 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →